Danimer Scientific Completes Dividend Distribution of Warrants to Stockholders

Rhea-AI Summary

Danimer Scientific has completed the pro-rata dividend distribution of warrants to holders of its Class A Common Stock as of May 13, 2024. Each shareholder received one Dividend Warrant for every three shares held, rounding down for fractional shares. The Dividend Warrants, trading under 'DNMRW' on the OTCQX market from July 15, 2024, can be exercised at an initial price of $5.00 per share. Holders can use cash or Convertible Notes to exercise the warrants until July 15, 2025. A Bonus Share Fraction offers an additional half share of Common Stock if exercised before the expiration date. The warrants are redeemable by the company after August 1, 2024, if certain conditions are met.

Positive

• Completed dividend warrants distribution to shareholders.
• Dividend Warrants trading separately under 'DNMRW' from July 15, 2024.
• Option to exercise warrants using cash or Convertible Notes.
• Bonus Share Fraction offers additional shares if warrants are exercised early.

Negative

• Potential dilution of shares if many Dividend Warrants are exercised.
• Redemption of warrants by the company could limit long-term benefits for shareholders.

BAINBRIDGE, Ga.--(BUSINESS WIRE)-- Danimer Scientific, Inc. (NYSE: DNMR) (“Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced the completion of a previously announced pro-rata dividend distribution of warrants (“Dividend Warrants”) to holders of the Company’s Class A Common Stock, par value $0.0001 per share (“Common Stock”), as of May 13, 2024 (“Record Date”). The stockholders of record as of the Record Date received one (1) Dividend Warrant for every three (3) shares of Common Stock held as of the Record Date, subject to downward rounding. Holders of our 3.250% Convertible Senior Notes due 2026 (“Convertible Notes”) and our pre-funded common stock purchase warrants dated March 25, 2024 (collectively, “other eligible recipients”) as of the Record Date received Dividend Warrants on a pass-through basis. As an example, a stockholder who owns 3,000 shares of Common Stock received 1,000 Dividend Warrants, and a stockholder who owns 1,000 shares of Common Stock received 333 Dividend Warrants. The Dividend Warrants are expected to trade on the OTCQX market commencing on July 15, 2024 under the anticipated symbol “DNMRW” and are separate from Danimer Scientific’s Common Stock, which will continue to trade on the New York Stock Exchange under the symbol “DNMR”.

The holders of the Dividend Warrants may exercise the Dividend Warrants by using cash or, during the periods and in the manner specified in the warrant agreement, the Company’s outstanding Convertible Notes. The Dividend Warrants include a provision that provides an additional one-half share of Common Stock to holders (“Bonus Share Fraction”) that exercise the Dividend Warrant prior to the Bonus Share Expiration Date (defined below).

Additional Details on Warrant Distribution

Each Dividend Warrant entitles the holder to purchase, at the holder’s sole and exclusive election, one share of Common Stock plus, if applicable and as described below, the Bonus Share Fraction, at an initial exercise price of $5.00 per share (the “Exercise Price”).

Dividend Warrant holders may exercise their Dividend Warrants with cash or, after July 26, 2024, with the Company’s Convertible Notes at face value, as specified under the terms of the warrant agreement filed with the U.S. Securities and Exchange Commission (“SEC”). Each $1,000 principal amount of Convertible Notes is equal to the aggregate Exercise Price of 200 Dividend Warrants. The right of Dividend Warrant holders to exercise their respective Dividend Warrants by delivering Convertible Notes will terminate on the Bonus Share Expiration Date.

The Dividend Warrants are redeemable by the Company, upon 20 calendar days’ notice, from and after the first trading day following the date on which the daily volume weighted average price (“VWAP”) of the shares of Common Stock has been at least equal to a specified price, initially equal to the Exercise Price, for at least 20 trading days each falling on or after August 1, 2024 (whether or not consecutive) out of 30 consecutive trading days. Any unredeemed Dividend Warrants will expire at 5:00 p.m. on July 15, 2025.

Additional Details on Bonus Share Fraction

The Bonus Share Fraction feature referenced above entitles a holder of a Dividend Warrant to receive an additional one-half of a share of Common Stock for each Dividend Warrant exercised under certain circumstances without payment of any additional exercise price. The right to receive the Bonus Share Fraction will expire at 5:00 p.m. New York City time on the first trading day (“Bonus Share Expiration Date”) following the date on which the VWAP of the shares of Common Stock has been at least equal to a specified price, initially $2.00 per share, for at least 20 trading days each falling on or after August 1, 2024 (whether or not consecutive) out of 30 consecutive trading days (“Bonus Share Expiration Price Condition”). Any Dividend Warrant exercised after the Bonus Share Expiration Date will not be entitled to the Bonus Share Fraction.

The Company will make a public announcement of the Bonus Share Expiration Date prior to market open on the Bonus Share Expiration Date if the Bonus Share Expiration Price Condition is met.

Other Information

A Q&A regarding this warrant distribution is available in the Investor Relations section of the Company’s website under the “Resources” tab, https://ir.danimerscientific.com/.

The distribution of the Dividend Warrants has not been registered under the Securities Act of 1933, as amended (“Securities Act”), because the issuance of a warrant for no consideration is not a sale or disposition of a security or interest in a security for value pursuant to Section 2(a)(3) of the Securities Act. The Company filed with the SEC a prospectus supplement, dated July 12, 2024, to the prospectus, dated June 5, 2024 (together, the “Prospectus”), each included within the Company’s existing shelf registration statement on Form S-3 (Reg. No. 333-279371), to register the shares of Common Stock underlying the Dividend Warrants.

B. Dyson Capital Advisors served as exclusive financial advisor on the Company’s distribution of the Dividend Warrants.

Gibson, Dunn & Crutcher LLP served as legal advisor to B. Dyson Capital Advisors.

Kane Kessler, P.C. served as legal advisor to the Company.

About Danimer Scientific

Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer’s technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, fibers, filaments, films and injection-molded articles, among others. Danimer holds more than 480 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, visit https://danimerscientific.com.

No Offer or Solicitation

This Press Release and the Q&A referenced in it shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A Form 8-A registration statement and the Prospectus describing the terms of the Dividend Warrants has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Warrant holders should read the Prospectus carefully, including the Risk Factors section included and incorporated by reference therein. This press release contains a general summary of the terms of the Dividend Warrants. The Prospectus and the warrant agreement describe the terms of the Dividend Warrants in more detail, and in the event of any inconsistency, the warrant agreement will govern the final terms of the Dividend Warrants. Please read the warrant agreement now that it is available, as it contains important information about the terms of the Dividend Warrants.

Forward‐Looking Statements

Please note that in this press release we may use words such as “appears,” “anticipates,” “believes,” “plans,” “expects,” “intends,” “future,” and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the number of warrants, if any, that will be exercised by warrant-holders. Forward-looking statements are made based on the Company’s expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to the Company’s expectations related to the use of proceeds from the equity offering; the overall level of consumer demand on the Company’s products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company’s customers; the Company’s ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to the Company’s products; the Company’s exposure to product liability or product warranty claims and other loss contingencies; the impact on the Company’s business, operations and financial results from the ongoing conflicts in Ukraine and the Middle East; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company’s ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, the Company’s information systems; the ability of the Company’s information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; the Company’s ability to properly maintain, protect, repair or upgrade its information technology systems or information security systems, or problems with the Company’s transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; the Company’s ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect the Company’s financial results is included from time to time in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements included in this press release are based upon information available to the Company as of the date of this press release and speak only as of the date hereof. The Company assumes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240712958053/en/

Investors

Blake Chamblee

Phone: 770-337-6570

ir@danimer.com

Media

Blake Chamblee

Phone: 770-337-6570

ir@danimer.com

Source: Danimer Scientific, Inc.

FAQ

What is the stock symbol for Danimer Scientific's warrants?

Danimer Scientific's Dividend Warrants trade under the symbol 'DNMRW' on the OTCQX market.

When is the record date for Danimer Scientific's dividend warrants?

The record date for the warrants is May 13, 2024.

How many Dividend Warrants did shareholders receive?

Shareholders received one Dividend Warrant for every three shares of Common Stock held.

What is the exercise price for the Dividend Warrants?

The initial exercise price for the warrants is $5.00 per share.

What is the Bonus Share Fraction for Danimer Scientific's warrants?

The Bonus Share Fraction allows an additional one-half share of Common Stock if the warrant is exercised before the expiration date under certain conditions.

When do Danimer Scientific's Dividend Warrants expire?

The Dividend Warrants expire on July 15, 2025.

Can Convertible Notes be used to exercise the Dividend Warrants?

Yes, Convertible Notes can be used to exercise the warrants after July 26, 2024, until the specified expiration date.

Under what conditions are the Dividend Warrants redeemable by the company?

The Dividend Warrants are redeemable by the company after August 1, 2024, if the daily volume-weighted average price of shares meets certain conditions for 20 trading days within 30 consecutive days.